Farokhzad Omid C, Karp Jeffrey M, Langer Robert
Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Expert Opin Drug Deliv. 2006 May;3(3):311-24. doi: 10.1517/17425247.3.3.311.
The combination of targeted drug delivery and controlled-release technology may pave the road for more effective yet safer chemotherapeutic options for cancer therapy. Drug-encapsulated polymeric nanoparticle-aptamer bioconjugates represent an emerging technology that can facilitate the delivery of chemotherapeutics to primary and metastatic tumours. Aptamers are short nucleic acid molecules with binding properties and biochemical characteristics that may make them suitable for use as targeting molecules. The goal of this review is to summarise the key components that are required for creating effective cancer targeting nanoparticle-aptamer bioconjugates. The field of controlled release and the structure and properties of aptamers, as well as the criteria for constructing effective conjugates, will be discussed.
靶向给药与控释技术的结合可能为癌症治疗带来更有效且更安全的化疗选择。药物包封的聚合物纳米颗粒-适配体生物共轭物是一种新兴技术，它可以促进化疗药物向原发性和转移性肿瘤的递送。适配体是具有结合特性和生化特征的短核酸分子，这可能使其适合用作靶向分子。本综述的目的是总结创建有效的癌症靶向纳米颗粒-适配体生物共轭物所需的关键组成部分。将讨论控释领域、适配体的结构和性质，以及构建有效共轭物的标准。
